EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preparation and Formulation of a New Therapeutic Supplement by the Combination of Dendritic Cells and IPI-549 (Eganelisib) for the Treatment of Breast Cancer in BALB/c Mice

Mohammad Mahdi Zangeneh, Reza Safaralizadeh, Mohammad A.H. Feizi, Nowruz Delirezh, Naser Abbasi

Jundishapur Journal of Natural Pharmaceutical Products · 02.10.2024 · 19 (4)

DOI: 10.5812/jjnpp-153561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Jundishapur Journal of Natural Pharmaceutical Products, online erschienen am 02.10.2024. Verfasst von Mohammad Mahdi Zangeneh und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

: Dendritic cell-based cancer immunotherapy is considered an innovative and promising approach aimed at enhancing the host's immune response to combat tumors. Additionally, IPI-549 has been identified as a first-line therapeutic option for breast cancer treatment. The objective of this research was to develop and formulate a novel therapeutic supplement by combining dendritic cells with IPI-549 (Eganelisib) for breast cancer treatment. The concurrent administration of dendritic cells and IPI-549 (DC-IPI) was utilized to treat mice and elicit immunological responses triggered by vaccination. Tumor regression and overall survival rates were evaluated across five distinct experimental groups. The administration of tumor cell lysate alongside DC-IPI resulted in a significant reduction in tumor growth and a two- to three-fold increase in the survival duration of treated mice. DC-IPI, whether decorated with mannan or not, elicited stronger responses in terms of delayed-type hypersensitivity, lymphocyte proliferation, and CD107a expression. Moreover, our findings demonstrated a reduction in IL-4 production in the supernatants of splenocyte cultures. A significant reduction in BRCA1 mRNA levels was also observed following treatment with DC-IPI. In conclusion, our results suggest that the DC-IPI antigen delivery system exhibited substantial anti-tumor efficacy in a breast cancer mouse model, representing a potential advancement in immunotherapy for human breast cancer.

Zitieren

APA

Zangeneh, M. M., Safaralizadeh, R., Feizi, M. A., Delirezh, N., & Abbasi, N. (2024). Preparation and Formulation of a New Therapeutic Supplement by the Combination of Dendritic Cells and IPI-549 (Eganelisib) for the Treatment of Breast Cancer in BALB/c Mice. Jundishapur Journal of Natural Pharmaceutical Products, 19(4). https://doi.org/10.5812/jjnpp-153561

Vancouver

Zangeneh MM, Safaralizadeh R, Feizi MA, Delirezh N, Abbasi N. Preparation and Formulation of a New Therapeutic Supplement by the Combination of Dendritic Cells and IPI-549 (Eganelisib) for the Treatment of Breast Cancer in BALB/c Mice. Jundishapur Journal of Natural Pharmaceutical Products. 2024;19(4). doi:10.5812/jjnpp-153561

BibTeX
@article{Zangeneh2024,
  author = {Zangeneh, Mohammad Mahdi and Safaralizadeh, Reza and Feizi, Mohammad A.H. and Delirezh, Nowruz and Abbasi, Naser},
  title = {Preparation and Formulation of a New Therapeutic Supplement by the Combination of Dendritic Cells and IPI-549 (Eganelisib) for the Treatment of Breast Cancer in BALB/c Mice},
  journal = {Jundishapur Journal of Natural Pharmaceutical Products},
  year = {2024},
  volume = {19},
  number = {4},
  doi = {10.5812/jjnpp-153561}
}
Kostenlos starten →